Relay Therapeutics Eyes Pivotal 2026 Milestones with Zovegalisib Data Readouts
Event summary
- Relay Therapeutics reported $554.5M in cash, cash equivalents, and investments as of Q4 2025, down from $781.3M in 2024.
- Initial Phase 1 data for zovegalisib in PIK3CA-driven vascular anomalies expected in the first half of 2026.
- Phase 1/2 data for zovegalisib + fulvestrant in CDK4/6-experienced breast cancer patients to be presented at ESMO TAT on March 16, 2026.
- 2025 revenue was $15.4M, up from $10.0M in 2024, driven by license agreements with Elevar and Genentech.
The big picture
Relay Therapeutics is entering a critical phase in 2026 with multiple clinical milestones for its lead candidate, zovegalisib. The company's focus on precision medicine aligns with broader industry trends toward targeted therapies, particularly in oncology and genetic diseases. With a strong cash position and upcoming data readouts, Relay aims to position itself as a key player in the PI3Kα inhibitor market, addressing significant unmet needs in breast cancer and vascular anomalies.
What we're watching
- Clinical Data Impact
- How the Phase 1/2 data for zovegalisib + fulvestrant will influence investor confidence and regulatory pathways.
- Cash Runway
- Whether Relay Therapeutics' $554.5M cash position will be sufficient to fund operations into 2029 as projected.
- Market Positioning
- The pace at which Relay Therapeutics can differentiate zovegalisib in the competitive landscape of PI3Kα inhibitors.
Related topics